Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Venus Healthcare Homes is exporting its integrated care-village model to Malaysia and across ASEAN, where demographic aging is compressing into a single decade—a timeline that demands infrastructure built for population-wide health maintenance rather than crisis management. The model positions healthy aging as an economic asset only when care systems reach beyond affluent populations to keep ordinary older people well and community-connected.
Function Health has launched a secure connector allowing users to feed personalized lab results and clinical notes into mainstream AI chatbots—ChatGPT, Claude, and Perplexity—enabling AI to provide answers grounded in individual biomarkers rather than population averages. This addresses a critical gap: AI health guidance has been generic and contextless, while over 80% of Function's members show at least one biomarker outside optimal ranges that warrant investigation and intervention.
Changes in older adults' digital technology use—particularly discontinuation—predict cognitive decline and depressive symptoms over time. This longitudinal analysis across multiple cohorts reveals that tracking shifts in technology engagement, rather than static user status alone, provides a more accurate window into emerging cognitive and emotional vulnerability in aging.
China's regulatory approval of lecanemab's subcutaneous formulation expands access to an amyloid-targeting monoclonal antibody for early Alzheimer's disease. The weekly self-injection regimen reduces treatment burden compared to intravenous administration, potentially increasing uptake among the estimated 17 million Chinese patients with mild cognitive impairment or mild dementia.
Akkermansia muciniphila, a gut bacterium that declines with age but remains abundant in healthy centenarians, extends healthspan through mechanisms that reinforce intestinal barrier integrity, restore metabolic balance, suppress chronic inflammation, and modulate immune function. Supplementation with this organism and its bioactive derivatives shows clinical efficacy in reversing age-related decline across neurodegenerative, metabolic, musculoskeletal, and vascular domains.
Annovis Bio exceeded enrollment targets for its Phase 3 trial of buntanetap, recruiting 850 patients against a goal of 760 for early Alzheimer's disease. The achievement demonstrates patient demand for novel therapeutics, though the drug's efficacy and regulatory approval remain unproven and contingent on data expected in early 2027.
LifespanningRx released the Peptide Explorer, a structured digital questionnaire that maps health goals across ten domains and flags potential peptide therapy candidates for clinician review. The tool screens responses against safety criteria before recommending further evaluation, positioning peptide therapy within a clinician-supervised framework rather than direct-to-consumer access.
Minicircle, a gene therapy company, advanced to the XPRIZE Healthspan finals with a non-viral circular DNA platform designed to address multiple aging phenotypes simultaneously—muscle decline, neuroinflammation, mitochondrial dysfunction, and immune dysregulation—in adults aged 50 to 80. The $1 million award will fund a placebo-controlled human trial to measure rejuvenation endpoints, representing a shift toward measurable, multisystem interventions in aging.
The Longevity Science Foundation has extended its Invested in Her campaign deadline to October 1, 2026, targeting $250,000 to fund early-stage research into ovarian aging and menopause—a critical gap in women's health science that receives less than 1% of NIH funding despite its systemic impact on cardiometabolic, neurological, and skeletal health across the lifespan.
Alterity Therapeutics secured a US composition-of-matter patent for ATH434 extending exclusivity to 2045, protecting the exact crystalline form used in clinical trials for Multiple System Atrophy. The patent strengthens the company's negotiating position for partnerships and creates a commercial foundation for expanding development into Parkinson's disease, a substantially larger patient population.
Oligomerix appointed an experienced pharmaceutical executive as interim CEO to advance its Alzheimer's pipeline, specifically its lead candidate OLX 07010, which demonstrated tau reduction in preclinical models and acceptable safety in Phase 1a human studies. The leadership transition positions the company to move from discovery into clinical-stage development of tau-targeting therapeutics.
Family caregivers of dementia patients in rural and remote areas experience significantly higher burden than urban counterparts, driven by isolation, limited access to support services, and financial strain. Understanding these regional disparities is essential for designing interventions that address the specific stressors affecting caregiver health and longevity.